Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Stage Breast Cancer | Zendy

Jennifer A. Ligibel | Zendy; Eric P. Winer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Stage Breast Cancer

Author(s) -

Jennifer A. Ligibel,

Eric P. Winer

Publication year - 2005

Publication title -

women s health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.363

H-Index - 39

eISSN - 1745-5065

pISSN - 1745-5057

DOI - 10.2217/17455057.2.1.89

Subject(s) - aromatase , medicine , adjuvant , breast cancer , tamoxifen , oncology , clinical trial , stage (stratigraphy) , adjuvant therapy , postmenopausal women , anastrozole , gynecology , hormonal therapy , aromatase inhibitor , cancer , biology , paleontology

This article summarizes the current data regarding the use of the aromatase inhibitors as adjuvant hormonal therapy for postmenopausal women with early stage breast cancer. The article focuses on the five major trials examining the use of these drugs and their toxicity in the adjuvant setting. The data currently available suggest that the aromatase inhibitors are efficacious, either as upfront therapy or after a course of tamoxifen. Ongoing trials will compare these approaches and guide the use of these agents in the years to come.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research